InvestSMART

Truscreen Group Limited (ASX: TRU) - Share Price

- Current share price for TRU : $0.012

TruScreen Group Limited (TRU) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli. Its cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly personnel and supporting laboratory infrastructure.

TRU General Information +

ASX Code TRU
Website http://www.truscreen.com
Industry/Sector Health Care Equipment
Market Cap ($M) 12
TRU Share Price $0.012
Day High $0.000
Day Low $0.000
Last Close $0.012
TRU Share Price Movement - ( No change )
Prices as at 16:40, 14 Aug 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Truscreen Group Limited (TRU) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield
Interim 17¢ 100% 15 Oct 2013 5 Nov 2013 - - -
Final 18¢ 100% 29 Apr 2013 17 May 2013 - - -
Interim 12¢ 100% 17 Oct 2012 8 Nov 2012 - - -

See all dividends from Truscreen Group Limited (TRU) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Truscreen Group Limited (TRU) price-sensitive announcements

TRU - Rights Issue Completes Substantially Oversubscribed
TruScreen Group Limited announced the successful completion of a substantially oversubscri
Truscreen Group Limited (TRU)
25 Jun 2026 | 11:48 AM
TRU - Milestone Markets Update
TruScreen Group Limited, a leader in AI-enabled cervical cancer screening, has released a
Truscreen Group Limited (TRU)
12 Jun 2026 | 7:30 AM
TRU - TruScreen Preliminary Final Results FY2026 Presentation
TruScreen Group Limited, an AI-enabled cervical cancer screening company, reported over NZ
Truscreen Group Limited (TRU)
29 May 2026 | 7:30 AM
TRU - TruScreen Preliminary Final Results FY2026
Truscreen Group Limited reported a 42% increase in product sales for FY2026, driven by an
Truscreen Group Limited (TRU)
29 May 2026 | 7:30 AM

Truscreen Group Limited (TRU) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Truscreen Group Limited (TRU)
ORDINARY FULLY PAID FOREIGN EXEMPT NZX
 Health Care $13 Top Twenty Shareholders 13 Aug 2026 10:38AM $0.012 $0.012 fallen by 0%
Truscreen Group Limited (TRU)
ORDINARY FULLY PAID FOREIGN EXEMPT NZX
 Health Care $13 African Expansion to Rwanda, Nigeria, Ghana,& Cote d'Ivoire 11 Aug 2026 9:02AM $0.013 $0.012 fallen by 7.69%
Truscreen Group Limited (TRU)
ORDINARY FULLY PAID FOREIGN EXEMPT NZX
 Health Care $13 Notification regarding unquoted securities - TRU 6 Aug 2026 7:30AM $0.013 $0.012 fallen by 4%
Truscreen Group Limited (TRU)
ORDINARY FULLY PAID FOREIGN EXEMPT NZX
 Health Care $13 Notification regarding unquoted securities - TRU 6 Aug 2026 7:30AM $0.013 $0.012 fallen by 4%
Truscreen Group Limited (TRU)
ORDINARY FULLY PAID FOREIGN EXEMPT NZX
 Health Care $13 Notice of Annual General Meeting/Proxy Form 5 Aug 2026 3:17PM $0.013 $0.012 fallen by 4%
Truscreen Group Limited (TRU)
ORDINARY FULLY PAID FOREIGN EXEMPT NZX
 Health Care $13 Notification of cessation of securities - TRU 4 Aug 2026 3:11PM $0.013 $0.012 fallen by 7.69%

TRU Financial Summary

Year to Mar NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$1.88 -$0.30 -25.70% 0.00 0.00 0.00% 0.0%
2025A -$2.04 -$0.40 -18.60% 0.00 0.00 0.00% 0.0%
2024A -$1.88 -$0.40 -21.80% 0.00 0.00 0.00% 0.0%

TRU Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
Cochlear Limited (COH) $8,759M 0.0171 -0.1894 0.0615 22.3802 27.6099 26.0094 3.21% 2.59% 2.69%
Fisher & Paykel Healthcare Corporation Limited (FPH) $20,708M 0.1388 0.1488 0.1882 53.3192 46.4131 39.0606 1.23% 1.33% 1.50%
ResMed Inc. (RMD) $18,805M 0.3087 9.7744 0.0800 218.7070 20.2987 18.7954 1.05% 1.13% 1.22%
Truscreen Group Limited (TRU) $13M -0.2571 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

TRU Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 4.29 0.00
Market 0.31 13.20 1.16 0.66
Sector 0.75 19.10 1.62 2.20

TRU Directors

Name Position Start Date
Mr Anthony (Tony) Peng Ho Executive Chairman, Executive Director 4 Oct 2018
Ms Christine Pears Non-Executive Director 11 Sep 2025
Dr Dexter Cheung Non-Executive Director 1 Mar 2021
Mr Reece O'Connel Non-Executive Director 3 Jun 2026

Truscreen Group Limited (TRU) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
27 Feb 2026 HO, Anthony (Tony) Buy Indirect Shares 500,000 $0.018 $9,121.000
20 Mar 2024 CHEUNG, Dexter Issued Direct Shares 167,777 $0.020 $3,356.000
20 Mar 2024 HO, Anthony (Tony) Issued Indirect Shares 2,223,333 $0.020 $44,467.000

See all changes in directors' interest & trades for Truscreen Group Limited (TRU) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

TRU Management

Name Position
Guy Adrian Robertson Chief Financial Officer,Company Secretary
Dr Jerry Tan General Manager Commercial
Martin Dillon Interim CEO
Dr Carolina Velasquez Medical Affairs and Training Manager
Usharani Raji Technology and Production Manager

TRU Calendar of Events

Date Event
28 June 2027 Report (Annual)
28 May 2027 Report (Prelim)
27 November 2026 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.